Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...

First Stem Cell and Genomics Laboratory (FSG), formerly known before as Hortman Stem Cell Laboratory and with the support of the Dubai Health Authority, is organising the third Dubai Stem Cell ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...

Its 3-year beta, a measure of volatility relative to the broader market, is 1.8. Related: Cathie Wood buys $37 million of surging tech stock. Over the past several years, Ark Fund ...